French health authorities announced on Friday that they had approved the Johnson & Johnson single dose COVID-19 vaccine for use in France. One day after it approved by European Union authorities.
In recent days we have seen the case of a 60-year-old woman in France who had recovered from breast cancer. Nadine Roger, who lives in Paris, is at risk of catching COVID-19 and wants to be vaccinated immediately. However, when she was offered a vaccine made by AstraZeneca, she declined.
“AstraZeneca (gunfire) scared me,” she said. Roger, a medical technician, said she would instead wait for US firm Johnson & Johnson vaccine. Which European regulators have yet to approve.
“J&J’s COVID-19 vaccine can use as part of France’s vaccination strategy in people over 18 years of age. Including people over 65 years old who may have the disease,” said Haute Autorite de Sante (HAS). ), he said in a statement.
Moreover, HAS said the vaccine was effective and well tolerated by patients. This is the fourth vaccine on the French market.
The European Medicines Agency (EMA) approved the J&J’s COVID-19 vaccine on Thursday, paving the way for the first injection of a month.
Johnson & Johnson Vaccine
This single use vaccine is manufacture by the Belgian company Janssen. This vaccine is an inexpensive alternative to the Pfizer and Moderna vaccines. And it can store it in the refrigerator, not in the freezer. Studies show that it prevents serious illness but is 66% effective overall when plausible cases are involved.
The company agreed to ship 100 million boxes to the US by the end of June. The first cans will be available to the American public as early as next week.
The UK, EU, and Canada have also ordered cans, and the Covax program has ordered 500 million cans for poor countries.
